1 · Why this LDV20 review starts before purchase

The earlier posts in this series walked readers through LDV20 from the inside: how to use the routine, the four-ingredient story, a real-world week in the life of one capsule a day, and how the product sits alongside other Australian cardiovascular listed medicines. This LDV20 review turns the camera around: it starts before the order is placed.

For an Australian consumer comparing options, the most useful pre-purchase discipline is the three-way cross-check between the pack itself, the public TGA register and the brand product page. Each holds information the others don't, but the three should line up exactly. Sections 2 to 5 below walk through that three-way cross-check in order; section 6 adds a routine-fit layer that only the consumer can complete; and section 7 turns the whole sequence into an offline checklist.

2 · The first 60 seconds — what the product packaging should show you

Australian listed-medicine packaging is regulated under the TGA labelling code. Before opening the order, a consumer can read five fixed elements directly off the box. The first 60 seconds are spent on these five, in this order:

If any of these five elements is missing, blurred or replaced, the product should be returned to the seller before opening the inner seal. The packaging itself is the first layer of the verification process.

3 · The AUST L 502251 cross-check on the TGA ARTG portal

With the AUST L number in hand — printed on the pack as AUST L 502251 — the second step is a public register lookup on the Therapeutic Goods Administration's Australian Register of Therapeutic Goods. The portal entry for LDV20 is at https://www.tga.gov.au/resources/artg/502251 and contains four verifiable fields:

• Sponsor — should read Pure Australia or its full name Pure Australia Pty Ltd
• Registration date — the date the listed-medicine entry was created
• Registration type — Listed Medicine
• Active ingredients — at least four should be listed; see section 4 for the exact botanical and chemical names

The same cross-check applies to every other Australian cardiovascular listed medicine: the pack and the public ARTG register entry should match each other line-for-line. A package that does not carry a verifiable AUST L entry is not part of the category this LDV20 review is comparing — it is outside the listed-medicine framework altogether.

4 · Reading the ingredient list line-for-line against the public ARTG entry

The four ingredients in LDV20 are recorded on the TGA ARTG entry using botanical and chemical names that the consumer can match directly against the pack. The exact names — taken from the public LDV20 ARTG record — are:

A genuine LDV20 product page matches this list line-for-line using the same names. If a pack shows a slightly different spelling — for example, "policosanol" written without the source description, or a chromium entry that doesn't specify the hexahydrate form — the consumer should ask the seller for clarification before assuming the product is the same AUST L 502251 entry.

The Policosanol anchor in this list is the most distinctive numerical field of the four ingredients. The product-page wording describes 20 mg per capsule as the maximum daily amount permitted under Australia's listed-medicine framework.

5 · How the brand-operated information pages support verification

Once the ARTG cross-check is done, the brand-operated information pages become the second verification layer. Pure Australia publishes three reference pages for LDV20 that sit alongside the public TGA entry:

• LDV20 product page — the canonical brand description of the formula, label-permitted wording, pack design and ingredients.
• LDV20 Official Information Center — the brand-side consolidated index for product facts, ARTG verification, label reminders and label-mandated cautions.
• LDV20 consumer FAQ — the brand-side consumer questions and answers, again aligned to the label wording.

Across these three pages, the same four ingredients, the same AUST L 502251 number, the same sponsor name and the same label-permitted language all reappear in the same wording as the TGA entry. When the pack, the public register and the brand pages all agree, the pre-purchase verification is complete.

6 · Routine-fit points to read on the pack before ordering

The pack also carries information that the public register does not list — practical, consumer-side fields that only the on-pack label can describe. These are the routine-fit fields that determine whether the product matches the consumer's normal day, and they are worth reading before the order is committed to.

• Dose per day — the LDV20 product page describes once daily with food. Reading the on-pack direction confirms the same routine for the pack in front of you.
• Total pack size — published on the Official Information Center as 120 capsules split into 4 × 30 sub-packs.
• Standard advisory block — printed within the TGA labelling code, identical across all Australian listed medicines.
• Storage note — printed on the pack; consumers in warmer Australian climates should check whether a cool, dry storage location is available for the four-month supply.

Beyond the label, the wider Australian routine references — the NHMRC's Australian Dietary Guidelines and the Australian Government's Physical Activity and Sedentary Behaviour Guidelines — describe the surrounding daily context a once-daily listed-medicine routine fits into. Reading these references in advance is the most efficient way to set realistic expectations for how a routine fits into a normal Australian day.

7 · A pre-purchase checklist Australian consumers can use offline

The full three-way cross-check compresses neatly into a checklist that can be ticked off in a few minutes. Print or copy this list, then work through it once per candidate product, including LDV20 and any other Australian cardiovascular listed medicine under consideration.

For LDV20, every item on this checklist resolves on the three-way cross-check described in sections 2 to 5. For a comparable listed medicine, the same checklist applies with the candidate's own product page, the candidate's own AUST L number and the candidate's own TGA ARTG entry. If any item does not resolve, the brand-side information pages are the first place to ask before the order is finalised.

9 · References

Australian regulators and public registers

• Therapeutic Goods Administration (TGA) — home
• TGA — Australian Register of Therapeutic Goods (ARTG)
• TGA ARTG — LDV20 (entry 502251)
• TGA — Listed medicines overview
• TGA — Good Manufacturing Practice (GMP)
• TGA — AUST numbers on medicine labels
• NHMRC — Australian Dietary Guidelines
• Australian Government — Physical Activity and Sedentary Behaviour Guidelines

Ingredient-level supporting literature (public records and reviews)

• Castaño G, et al. (2001) — Policosanol 20 vs 40 mg/day dose-finding study
• 2017 sugarcane-derived policosanol meta-analysis
• Zhao JV, et al. (2021) — Effect of Berberine on Cardiovascular Disease Risk Factors (Nutrients, MDPI)
• Xia LM, et al. (2016) — Study progress of berberine for treating cardiovascular disease
• NCBI Bookshelf — Milk Thistle (StatPearls, 2024)
• NIH Office of Dietary Supplements — Chromium fact sheet for health professionals

Pure Australia internal pages referenced in this article

• Pure Australia — home
• LDV20 product page
• LDV20 Official Information Center
• LDV20 consumer FAQ
• Pure Australia blog / news index